Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 11, 2002, Pages 1035-1039

  Wright, Christine E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Arteriogenesis; Calf blood pressure ratio; Gene transfer; Peripheral vascular disease; Reactive hyperaemia; Unilateral hindlimb ischaemia; Vascular endothelial growth factor; VEGFA; VEGFB

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B;

ANIMAL MODEL; ARTERY LIGATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEMORAL ARTERY; GENE TRANSFER; HINDLIMB; HYPEREMIA; LIMB ISCHEMIA; MALE; MEASUREMENT; NONHUMAN; RABBIT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; FEMALE; GENE TRANSFER TECHNIQUES; HINDLIMB; ISCHEMIA; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 0036400306     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03773.x     Document Type: Conference Paper

References (31)

1. Violi F, Criqui M, Longoni A, Castiglioni C, for the ADEP Group. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the ADEP Study. Atherosclerosis 1996; 120: 25-35.
2. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP, for the Vascular Clinical Trialists. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Circulation 1995; 92: 614-21.
3. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-85. Br. J. Clin. Pharmacol. 1988; 26: 569-76.
4. Salmasi A-M, Salmasi S, MacDonald G, Nicolaides AN. Improvement of silent myocardial ischaemia and reduction of plasma fibrinogen during nisoldipine therapy in occult coronary arterial disease. Int. J. Cardiol. 1991; 31: 71-80.
5. Randi ML, Mares M, Fabris F, Tison T, Barbone E, Girolami A. Decrease in fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine. Drug Res. 1991; 41: 414-16.
6. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis: A new concept for the treatment of arterial occlusive disease. Cardiovasc. Res. 2001; 49: 543-53.
7. Emanueli C, Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: Achievements and future directions. Br. J. Pharmacol. 2001; 133: 951-8.
8. Höckel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therapeutic angiogenesis. Arch. Surg. 1993; 128: 423-9.
9. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
10. Ito WD, Arras M, Scholz D, Winkler B, Htun P, Schaper W. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am. J. Physiol. 1997; 273: H1255-65.
11. Hoefer IE, van Royen N, Buschmann IR, Piek JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc. Res. 2001; 49: 609-17.
12. Isner JM. The role of angiogenic cytokines in cardiovascular disease. Clin. Immunol. Immunopathol. 1996; 80 (Suppl.): S82-91.
13. Olofsson B, Pajusola K, Kaipainen A et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 1996; 93: 2576-81.
14. Witzenbichler B, Asahara T, Murohara T et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998; 153: 381-94.
15. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 1998; 95: 548-53.
16. Olofsson B, Korpelainen E, Pepper MS et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl Acad. Sci. USA 1998; 95: 11709-14.
17. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994; 93: 662-70.
18. Takeshita S, Weir L, Chen D et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 1996; 227: 628-35.
19. Wright CE, Angus JA. Techniques to measure pharmacodynamics in the intact vasculature. J. Pharmacol. Toxicol. Methods 2000; 44: 385-94.
20. Wright CE, Angus JA. Effect of hypertension and hypercholesterolemia on vasodilatation in the rabbit. Hypertension 1986; 8: 361-71.
21. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 1990; 18: 5322.
22. Walder CE, Errett CJ, Bunting S et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J. Cardiovasc. Pharmacol. 1996; 27: 91-8.
23. Hershey JC, Baskin EP, Glass JD et al. Revascularization in the rabbit hindlimb. Dissociation between capillary sprouting and angiogenesis. Cardiovasc. Res. 2001; 49: 618-25.
24. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ. Res. 1997; 80: 829-37.
25. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 1998; 101: 40-50.
26. Feinberg RL, Gregory RT, Wheeler JR et al. The ischemic window. A method for the objective quantitation of the training effect in exercise therapy for intermittent claudication. J. Vasc. Surg. 1992; 16: 244-50.
27. Van Belle E, Rivard A, Chen D et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96: 2667-74.
28. Rubio R, Berne RM, Katori M. Release of adenosine in reactive hyperemia of the dog heart. Am. J. Physiol. 1969; 216: 56-62.
29. Yamabe H, Okumura K, Ishizaka H, Tsuchiya T, Yasue H. Role of endothelium-derived nitric oxide in myocardial reactive hyperemia. Am. J. Physiol. 1992; 263: H8-14.
30. Banitt PF, Smits P, Williams SB, Ganz P, Creager MA. Activation of ATP-sensitive potassium channels contributes to reactive hyperemia in humans. Am. J. Physiol. 1996; 271: H1594-8.
31. Wright CE, Angus JA. Enhanced total peripheral vascular responsiveness in hypertension accords with the amplifier hypothesis. J. Hypertens. 1999; 17: 1687-96.